Svmuu News Nasdaq Listed company Canton Strategic Holdings announced that the sale of its biotechnology R&D division, Gravitas Life Sciences, has been completed. The buyer in this transaction was Gravitas Collective Corp. The deal was unanimously approved by the company’s board of directors and officially closed on July 17, 2026.
This divestiture represents a key strategic transformation for the company. Moving forward, the company will focus on the Canton Network ecosystem, transitioning into a digital service provider for financial markets. It will prioritize the implementation of asset tokenization and financial digitization while continuing to enhance its compliant financial infrastructure business. (PRNewswire)